[go: up one dir, main page]

MX2012004337A - Formulaciones en aerosol medicinales mejoradas. - Google Patents

Formulaciones en aerosol medicinales mejoradas.

Info

Publication number
MX2012004337A
MX2012004337A MX2012004337A MX2012004337A MX2012004337A MX 2012004337 A MX2012004337 A MX 2012004337A MX 2012004337 A MX2012004337 A MX 2012004337A MX 2012004337 A MX2012004337 A MX 2012004337A MX 2012004337 A MX2012004337 A MX 2012004337A
Authority
MX
Mexico
Prior art keywords
medicinal aerosol
aerosol formulations
improved medicinal
micronized
hfa propellant
Prior art date
Application number
MX2012004337A
Other languages
English (en)
Inventor
Rudi Mueller-Walz
Lise-Marie Fueg
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012004337(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of MX2012004337A publication Critical patent/MX2012004337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una formulación de suspensión en aerosol medicinal para administración de MDI, que comprende: a) agonista ß2 micronizado; b) corticosteroide micronizado; c) una cantidad subterapéutica de un excipiente depurador de humedad; y d) un propulsor HFA; en donde (a), (b) y (c) y sus cantidades respectivas relativas se eligen de manera tal que se asocian para formar flóculos que tienen una densidad sustancialmente igual que la del propulsor HFA.
MX2012004337A 2009-10-16 2010-10-15 Formulaciones en aerosol medicinales mejoradas. MX2012004337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918149.6A GB0918149D0 (en) 2009-10-16 2009-10-16 Improved medicinal aerosol formulation
PCT/EP2010/065573 WO2011045432A1 (en) 2009-10-16 2010-10-15 Improved medicinal aerosol formulations

Publications (1)

Publication Number Publication Date
MX2012004337A true MX2012004337A (es) 2012-08-31

Family

ID=41462450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004337A MX2012004337A (es) 2009-10-16 2010-10-15 Formulaciones en aerosol medicinales mejoradas.

Country Status (26)

Country Link
US (3) US20120282189A1 (es)
EP (3) EP2488158B1 (es)
JP (6) JP2013507430A (es)
CN (1) CN102665675B (es)
AU (1) AU2010305698C9 (es)
BR (1) BR112012008983A2 (es)
CA (1) CA2776359C (es)
CL (1) CL2012000947A1 (es)
CY (1) CY1116109T1 (es)
DK (2) DK2488158T3 (es)
ES (2) ES2533372T3 (es)
FI (1) FI2881108T3 (es)
GB (1) GB0918149D0 (es)
HR (2) HRP20150174T1 (es)
HU (1) HUE065583T2 (es)
IL (1) IL219161B (es)
LT (1) LT2881108T (es)
MX (1) MX2012004337A (es)
NZ (1) NZ599901A (es)
PL (2) PL2488158T3 (es)
PT (2) PT2881108T (es)
RS (2) RS65391B1 (es)
SI (2) SI2881108T1 (es)
SM (2) SMT202400119T1 (es)
WO (1) WO2011045432A1 (es)
ZA (1) ZA201202452B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TWI495466B (zh) * 2010-09-23 2015-08-11 Intech Biopharm Ltd 用於氣喘之吸入性複方組合物
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2503962A1 (de) 1975-01-31 1976-08-05 Thomae Gmbh Dr K Spruehbare mittel in suspensionsform zur anwendung auf der haut
FR2420972A1 (fr) 1978-03-31 1979-10-26 Roussel Uclaf Application du peroxyde de thenoyle a titre de medicament
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
DE2914181C2 (de) 1979-04-07 1982-06-16 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie
JPS6135815A (ja) 1984-07-28 1986-02-20 Sanshin Seisakusho:Kk 上部集液式加圧ろ過機に於ける機体内液の脱液方法及び同装置
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
NZ246421A (en) * 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
DE4321288A1 (de) 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
WO1995015151A1 (en) 1993-12-02 1995-06-08 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
EP1908488A3 (en) 1995-04-14 2008-04-16 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
JP3707107B2 (ja) 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
AU725625B2 (en) 1997-01-30 2000-10-19 Alpenstock Holdings Limited A composition
EP1014943B1 (de) 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DK1131059T3 (da) 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
BR0015884A (pt) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002007672A2 (en) * 2000-07-19 2002-01-31 Aeropharm Technology, Inc. A medicinal aerosol formulation
CA2417973A1 (en) 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
HUP0302311A3 (en) 2000-10-09 2006-07-28 3M Innovative Properties Co Medicinal aerosol formulations
DE50211045D1 (de) 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TWI324934B (en) 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
GB0201400D0 (en) 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
KR100947409B1 (ko) 2002-03-01 2010-03-12 키에시 파르마슈티시 엣스. 피. 에이. 포모테롤 초미세 조성물
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
EP2319585A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium
WO2005004927A2 (en) 2003-07-12 2005-01-20 Jong-Hun Han An aromatic emitting apparatus for using cigarjack
EA200600598A1 (ru) 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CA2581999C (en) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
GB0918150D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
JP2015036045A (ja) * 2013-08-12 2015-02-23 株式会社泉技研 骨質改善のための超音波音響システム及び超音波音響機器の作動方法

Also Published As

Publication number Publication date
CN102665675A (zh) 2012-09-12
CA2776359A1 (en) 2011-04-21
NZ599901A (en) 2013-08-30
AU2010305698A1 (en) 2012-04-26
US10471077B2 (en) 2019-11-12
JP6568511B2 (ja) 2019-08-28
IL219161B (en) 2019-12-31
GB0918149D0 (en) 2009-12-02
US20170189423A1 (en) 2017-07-06
JP2019182878A (ja) 2019-10-24
US20120282189A1 (en) 2012-11-08
EP2881108A1 (en) 2015-06-10
AU2010305698C9 (en) 2014-04-17
SI2488158T1 (sl) 2015-04-30
SMT202400119T1 (it) 2024-05-14
CL2012000947A1 (es) 2012-12-14
ZA201202452B (en) 2013-09-25
PT2488158E (pt) 2015-03-16
HK1211207A1 (en) 2016-05-20
DK2488158T3 (en) 2015-03-23
PL2488158T3 (pl) 2015-06-30
CY1116109T1 (el) 2017-02-08
JP2023026517A (ja) 2023-02-24
JP2017057223A (ja) 2017-03-23
IL219161A0 (en) 2012-06-28
EP4327807A2 (en) 2024-02-28
DK2881108T3 (da) 2024-03-11
PT2881108T (pt) 2024-03-13
US20140314684A1 (en) 2014-10-23
JP2013507430A (ja) 2013-03-04
SI2881108T1 (sl) 2024-04-30
SMT201500052B (it) 2015-05-05
ES2533372T3 (es) 2015-04-09
PL2881108T3 (pl) 2024-06-17
HUE065583T2 (hu) 2024-06-28
CN102665675B (zh) 2014-03-19
RS65391B1 (sr) 2024-04-30
LT2881108T (lt) 2024-04-10
HRP20150174T1 (hr) 2015-05-22
AU2010305698B2 (en) 2012-12-20
EP2488158A1 (en) 2012-08-22
EP2881108B1 (en) 2023-12-27
AU2010305698C1 (en) 2013-07-25
HK1173077A1 (en) 2013-05-10
ES2973882T3 (es) 2024-06-24
FI2881108T3 (fi) 2024-03-13
JP7203701B2 (ja) 2023-01-13
RS53883B1 (sr) 2015-08-31
BR112012008983A2 (pt) 2016-04-05
JP2025148616A (ja) 2025-10-07
CA2776359C (en) 2015-12-08
HRP20240402T1 (hr) 2024-06-07
JP2015129162A (ja) 2015-07-16
EP4327807A3 (en) 2024-04-24
WO2011045432A1 (en) 2011-04-21
EP2488158B1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
CR20110435A (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidina-3-il) isoindolina-1,3-diona
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
EA201190092A1 (ru) Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me)
CU24355B1 (es) Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
WO2014097151A3 (en) Autotaxin inhibitors
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
UY33380A (es) Formulaciones farmacéuticas que contienen derivados de 1-(b(beta)-d-glucopiranosilo) y sus usos
EA201790525A1 (ru) Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства
BRPI0806713A8 (pt) Composições de tiacumicinas estáveis
MX2013001677A (es) Formulaciones estables de linaclotida.
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
MX2012004337A (es) Formulaciones en aerosol medicinales mejoradas.
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2019004001A (es) Compuestos de 2-amino-n- (arilsulfinil)-acetamida como inhibidores de la aminoacil-arnt sintetasa bacteriana.
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
IN2014DN01619A (es)
TN2009000510A1 (en) Extended release formulation of nevirapine
MX2010008852A (es) Formulaciones de flibanserina.
BR112014026817A2 (pt) derivados do pantotenato para o tratamento de transtornos neurológicos
PH12016500693A1 (en) Slow-release solid oral compositions
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
EA201190243A1 (ru) Стабильная фармацевтическая композиция флударабина фосфата

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted